Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for M-CSF/CSF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | M-CSF/CSF1 Recombinant Protein HEK293 expressed (native homodimer glycosylation), High Purity (>95%), Endotoxin Controlled (<1 EU/μg), Sequence Verified. Available in various tags. |
View CSF1 Products |
| Gene Delivery | M-CSF/CSF1 Promise-ORF / Lentivirus Full-length ORF expression particles for stable cell line generation and target overexpression. |
View CSF1 Products |
| Benchmark Ab | Anti-M-CSF/CSF1 Recombinant Antibody Recombinant benchmark antibody (derived from Carlumab sequence) for positive control and assay validation. |
View CSF1 Products |
| Validator | M-CSF/CSF1 siRNA Set Target-specific siRNA pool for gene knockdown and specificity verification. |
View CSF1 Products |
| Related Target A | CSF1R (CD115) The primary cognate receptor of M-CSF/CSF1. Critical for blocking-activity assays and receptor-ligand interaction screening. |
View CSF1R Products |
| Related Target B | IL34 Alternative high-affinity ligand for CSF1R. Screening against IL34 is essential to evaluate the therapeutic selectivity of CSF1R/M-CSF axis inhibitors. |
View IL34 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Homodimer Conformation | HEK293 mammalian expression system guarantees correct disulfide-linked homodimer formation and native-like glycosylation. |
| Cross-Species Cross-Reactivity Screening | Human, Cynomolgus, and Mouse ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Lack of Controls | Clinical benchmark antibodies (biosimilars) included for assay calibration. |
| False Positives | Sequence-verified siRNA included for target validation and phenotypic specificity checks. |
Live M-CSF/CSF1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the M-CSF/CSF1-CSF1R axis remains a cornerstone in modulating the tumor microenvironment (TME), particularly in depleting immunosuppressive tumor-associated macrophages (TAMs). The race for M-CSF/CSF1 therapeutics is intensifying, with major players shifting focus from traditional systemic monoclonal antibodies to combination regimens with immune checkpoint inhibitors (such as anti-PD-1/PD-L1) and novel bispecific formats. As first-generation therapies reach the clinic, the next wave of R&D is targeting localized delivery and selective isoform blockade to mitigate systemic toxicities like Kupffer cell depletion and facial edema.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Janssen (Carlumab), ImClone Systems | Solid Tumors, Osteolytic Diseases, Inflammatory Arthritis | Ligand-receptor blocking assays (Need high-purity, native homodimeric M-CSF and CSF1R proteins) |
| Bispecific Antibody / Fusion Protein | Synermore, Roche | Advanced Refractory Malignancies | Simultaneous binding validation (Need sequence-verified antigens for cross-reactivity and affinity profiling) |
| Small Molecule Inhibitor (CSF1R) | Daiichi Sankyo (Pexidartinib), Deciphera | Tenosynovial Giant Cell Tumor (TGCT), Pigmented Villonodular Synovitis | Selectivity assays against related kinases (Need native CSF1R intracellular domain or stable reporter cell lines) |